Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line.
The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincare.
“Once again, I am excited to see that Aesthetics Biomedical’s innovations have been validated by the issuance of a new patent, further strengthening our SoME Skincare brand and patent portfolio,” says Aesthetics Biomedical Inc.’s Founder & Chief Executive Officer MaryAnn Guerra in a news release. “Our SoME® Skincare product line will be expanded to fully utilize the broader patent coverage, under the leadership of our Director of Innovation & Design, Shaun Wootten.”
SoME Skincare, medically dispensed through professional offices, with its unique technology platform combines the body’s own regenerative cytokines within skincare. SoME Skincare has been clinically shown to improve both visual and cellular facial aging, according to the company.
“This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedical’s product portfolio,” adds Shaun Wootten, Director of Innovation and Design. “This is Aesthetics Biomedical’s broadest patent yet on the matter and cements the ingenuity of our Center of Aesthetic Innovation.”
The growth factors, derived from Platelet Rich Plasma [PRP] infused within its advanced formula signals the biochemical receptors on the cell surface to stimulate new collagen and new elastin for regeneration and repair of photodamaged skin to produce a personalized, autologous skincare treatment.
Aesthetics Biomedical Inc. is continuing to build its pipeline of regenerative products with a focus on skin, hair and nail personalized products. The patents cover multiple delivery systems including, gel, cream, ointment, and spray. This is coupled with the PRP serving as a rich source of exosomes that provide a natural comprehensive means for regeneration.
“The additional patent protection offered for SoME Skincare, will continue to provide Aesthetics Biomedical with a unique technology platform consisting of stabilized platelet rich plasma, permitting Aesthetics Biomedical to develop a multitude of topical products for various skin conditions including facial anti-aging,” says Lawrence A Rheins PhD, Aesthetics Biomedical Inc.’s Chief Scientific Officer.
